 Michael Rosenberg
Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Long QT Syndrome | 9 | 2025 | 67 | 5.260 |
Why?
| | Atrial Fibrillation | 12 | 2024 | 376 | 3.670 |
Why?
| | Machine Learning | 8 | 2023 | 443 | 2.060 |
Why?
| | Electrocardiography | 10 | 2024 | 611 | 1.860 |
Why?
| | Electronic Health Records | 6 | 2025 | 973 | 1.620 |
Why?
| | Anti-Arrhythmia Agents | 3 | 2023 | 112 | 1.460 |
Why?
| | Body Height | 5 | 2017 | 192 | 1.350 |
Why?
| | Decision Support Systems, Clinical | 2 | 2025 | 205 | 1.340 |
Why?
| | Multifactorial Inheritance | 2 | 2024 | 150 | 1.330 |
Why?
| | Torsades de Pointes | 4 | 2024 | 22 | 1.140 |
Why?
| | Ventricular Premature Complexes | 2 | 2025 | 36 | 1.100 |
Why?
| | Cardiomyopathies | 2 | 2025 | 340 | 1.050 |
Why?
| | Defibrillators, Implantable | 7 | 2020 | 300 | 1.040 |
Why?
| | Phenethylamines | 2 | 2024 | 23 | 0.880 |
Why?
| | Death, Sudden, Cardiac | 6 | 2019 | 179 | 0.810 |
Why?
| | Tachycardia, Ventricular | 4 | 2022 | 168 | 0.790 |
Why?
| | Arrhythmias, Cardiac | 4 | 2019 | 320 | 0.750 |
Why?
| | Medical Order Entry Systems | 1 | 2021 | 44 | 0.690 |
Why?
| | Sulfonamides | 2 | 2024 | 497 | 0.670 |
Why?
| | Sotalol | 1 | 2019 | 6 | 0.660 |
Why?
| | Ventricular Dysfunction, Left | 4 | 2025 | 385 | 0.650 |
Why?
| | Aged | 22 | 2025 | 22061 | 0.640 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2017 | 2060 | 0.630 |
Why?
| | Risk Factors | 18 | 2025 | 9786 | 0.620 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 171 | 0.610 |
Why?
| | Tachycardia, Supraventricular | 2 | 2021 | 44 | 0.610 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2022 | 321 | 0.600 |
Why?
| | Dihydrotestosterone | 1 | 2018 | 41 | 0.590 |
Why?
| | Risk Assessment | 6 | 2024 | 3262 | 0.580 |
Why?
| | Pacemaker, Artificial | 4 | 2023 | 110 | 0.570 |
Why?
| | Electrocardiography, Ambulatory | 2 | 2019 | 58 | 0.550 |
Why?
| | Decision Support Techniques | 1 | 2019 | 398 | 0.500 |
Why?
| | Humans | 46 | 2025 | 129625 | 0.490 |
Why?
| | Heart Rate | 1 | 2019 | 802 | 0.490 |
Why?
| | Peptide Fragments | 3 | 2014 | 693 | 0.480 |
Why?
| | Catheter Ablation | 4 | 2024 | 336 | 0.480 |
Why?
| | Male | 29 | 2025 | 63670 | 0.450 |
Why?
| | Endonucleases | 1 | 2014 | 28 | 0.450 |
Why?
| | Accessory Atrioventricular Bundle | 1 | 2014 | 13 | 0.450 |
Why?
| | Procollagen | 1 | 2014 | 21 | 0.440 |
Why?
| | Female | 28 | 2025 | 68734 | 0.440 |
Why?
| | Heart Failure | 2 | 2023 | 2133 | 0.430 |
Why?
| | Middle Aged | 16 | 2025 | 31136 | 0.410 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1021 | 0.410 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2014 | 158 | 0.410 |
Why?
| | Heart Failure, Diastolic | 1 | 2012 | 21 | 0.400 |
Why?
| | Atrial Flutter | 2 | 2024 | 35 | 0.400 |
Why?
| | Genome-Wide Association Study | 3 | 2018 | 1326 | 0.400 |
Why?
| | Incidence | 6 | 2021 | 2641 | 0.390 |
Why?
| | Atrioventricular Block | 2 | 2023 | 35 | 0.360 |
Why?
| | Coronary Disease | 1 | 2013 | 385 | 0.360 |
Why?
| | Transcatheter Aortic Valve Replacement | 2 | 2023 | 121 | 0.330 |
Why?
| | Atherosclerosis | 1 | 2013 | 402 | 0.320 |
Why?
| | Aortic Valve Stenosis | 2 | 2023 | 218 | 0.300 |
Why?
| | Inpatients | 2 | 2025 | 475 | 0.300 |
Why?
| | Exercise | 2 | 2018 | 1928 | 0.290 |
Why?
| | Echocardiography | 2 | 2025 | 634 | 0.290 |
Why?
| | Proportional Hazards Models | 5 | 2018 | 1198 | 0.270 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 2274 | 0.270 |
Why?
| | Heart Conduction System | 2 | 2024 | 95 | 0.260 |
Why?
| | Case-Control Studies | 3 | 2024 | 3378 | 0.250 |
Why?
| | Stroke Volume | 2 | 2025 | 592 | 0.230 |
Why?
| | Logistic Models | 2 | 2020 | 1986 | 0.220 |
Why?
| | Basketball | 1 | 2023 | 18 | 0.210 |
Why?
| | Longitudinal Studies | 3 | 2018 | 2720 | 0.210 |
Why?
| | United States | 6 | 2019 | 13871 | 0.200 |
Why?
| | Pilot Projects | 3 | 2018 | 1592 | 0.200 |
Why?
| | Electric Countershock | 1 | 2023 | 105 | 0.200 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2014 | 99 | 0.200 |
Why?
| | Metoprolol | 1 | 2022 | 39 | 0.190 |
Why?
| | Prospective Studies | 5 | 2019 | 7135 | 0.190 |
Why?
| | Diastole | 2 | 2012 | 148 | 0.190 |
Why?
| | Retrospective Studies | 11 | 2024 | 14522 | 0.190 |
Why?
| | Tachycardia, Atrioventricular Nodal Reentry | 1 | 2021 | 30 | 0.180 |
Why?
| | Sex Factors | 3 | 2018 | 1970 | 0.180 |
Why?
| | Cluster Analysis | 1 | 2022 | 482 | 0.180 |
Why?
| | Adult | 8 | 2024 | 35599 | 0.180 |
Why?
| | Biomarkers | 3 | 2018 | 3968 | 0.170 |
Why?
| | Artificial Intelligence | 1 | 2023 | 245 | 0.170 |
Why?
| | Drug Dosage Calculations | 1 | 2019 | 22 | 0.160 |
Why?
| | Myostatin | 2 | 2009 | 16 | 0.160 |
Why?
| | Contraindications, Procedure | 1 | 2019 | 11 | 0.160 |
Why?
| | Cell Phone | 1 | 2020 | 70 | 0.160 |
Why?
| | Bradycardia | 1 | 2019 | 53 | 0.160 |
Why?
| | Hypertension | 2 | 2022 | 1243 | 0.160 |
Why?
| | Tachycardia | 2 | 2021 | 57 | 0.160 |
Why?
| | Decision Trees | 1 | 2018 | 90 | 0.150 |
Why?
| | Time Factors | 3 | 2019 | 6555 | 0.150 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2018 | 53 | 0.150 |
Why?
| | Drug Monitoring | 1 | 2019 | 215 | 0.150 |
Why?
| | Nonlinear Dynamics | 1 | 2018 | 88 | 0.140 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 1947 | 0.140 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5075 | 0.130 |
Why?
| | Frailty | 1 | 2019 | 152 | 0.130 |
Why?
| | Metabolic Diseases | 1 | 2017 | 104 | 0.130 |
Why?
| | Patient Safety | 1 | 2019 | 287 | 0.130 |
Why?
| | Body Weights and Measures | 1 | 2016 | 35 | 0.130 |
Why?
| | Follow-Up Studies | 4 | 2024 | 4894 | 0.120 |
Why?
| | Down-Regulation | 1 | 2018 | 636 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2011 | 0.120 |
Why?
| | Treatment Outcome | 5 | 2023 | 10219 | 0.120 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2015 | 45 | 0.120 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 212 | 0.120 |
Why?
| | Physicians | 1 | 2023 | 866 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1499 | 0.110 |
Why?
| | Sirtuin 2 | 1 | 2014 | 24 | 0.110 |
Why?
| | Prosthesis Implantation | 1 | 2015 | 146 | 0.110 |
Why?
| | Algorithms | 1 | 2021 | 1616 | 0.110 |
Why?
| | Primary Prevention | 1 | 2015 | 190 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 287 | 0.100 |
Why?
| | Cardiac Pacing, Artificial | 2 | 2023 | 86 | 0.100 |
Why?
| | Atrial Function, Left | 1 | 2012 | 7 | 0.100 |
Why?
| | Longevity | 1 | 2014 | 155 | 0.100 |
Why?
| | Prognosis | 2 | 2018 | 3774 | 0.100 |
Why?
| | Epidemiologic Methods | 1 | 2012 | 74 | 0.100 |
Why?
| | Aged, 80 and over | 3 | 2019 | 7052 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 834 | 0.090 |
Why?
| | Prevalence | 1 | 2018 | 2564 | 0.090 |
Why?
| | Fibrosis | 1 | 2014 | 526 | 0.090 |
Why?
| | Nuclear Receptor Co-Repressor 1 | 1 | 2011 | 16 | 0.090 |
Why?
| | Receptors, Thyroid Hormone | 1 | 2011 | 21 | 0.090 |
Why?
| | Echocardiography, Doppler | 1 | 2011 | 108 | 0.090 |
Why?
| | Age Factors | 1 | 2018 | 3152 | 0.090 |
Why?
| | Thyroid Hormones | 1 | 2011 | 55 | 0.090 |
Why?
| | Population Surveillance | 1 | 2013 | 439 | 0.090 |
Why?
| | Thyroid Gland | 1 | 2011 | 95 | 0.090 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2009 | 306 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2015 | 781 | 0.080 |
Why?
| | Blood Flow Velocity | 1 | 2011 | 406 | 0.080 |
Why?
| | Heart | 2 | 2010 | 641 | 0.080 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 764 | 0.080 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2011 | 181 | 0.080 |
Why?
| | Cardiomegaly | 1 | 2010 | 172 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 851 | 0.080 |
Why?
| | Anti-Infective Agents, Local | 1 | 2009 | 42 | 0.080 |
Why?
| | Ventricular Fibrillation | 1 | 2009 | 57 | 0.080 |
Why?
| | Aortic Valve | 2 | 2023 | 347 | 0.070 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2009 | 187 | 0.070 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2009 | 132 | 0.070 |
Why?
| | Gene Deletion | 1 | 2009 | 382 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2019 | 2477 | 0.070 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2010 | 398 | 0.070 |
Why?
| | Young Adult | 2 | 2023 | 12455 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2009 | 432 | 0.070 |
Why?
| | Myocytes, Cardiac | 1 | 2010 | 499 | 0.060 |
Why?
| | Ethanol | 1 | 2009 | 591 | 0.060 |
Why?
| | Bundle of His | 1 | 2023 | 17 | 0.050 |
Why?
| | Bundle-Branch Block | 1 | 2023 | 30 | 0.050 |
Why?
| | Heart Atria | 1 | 2024 | 129 | 0.050 |
Why?
| | Mice | 5 | 2014 | 16961 | 0.050 |
Why?
| | Nebivolol | 1 | 2022 | 9 | 0.050 |
Why?
| | Atrioventricular Node | 1 | 2021 | 15 | 0.050 |
Why?
| | Focus Groups | 1 | 2023 | 450 | 0.040 |
Why?
| | Remote Sensing Technology | 1 | 2020 | 16 | 0.040 |
Why?
| | Mice, Knockout | 3 | 2014 | 2881 | 0.040 |
Why?
| | Electronics | 1 | 2020 | 74 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 506 | 0.040 |
Why?
| | Aging | 1 | 2009 | 1778 | 0.040 |
Why?
| | Survival Analysis | 2 | 2014 | 1269 | 0.040 |
Why?
| | Body Mass Index | 2 | 2017 | 2274 | 0.040 |
Why?
| | Blotting, Western | 2 | 2011 | 1206 | 0.030 |
Why?
| | Mendelian Randomization Analysis | 1 | 2017 | 47 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2018 | 353 | 0.030 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2015 | 86 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 997 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1872 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1019 | 0.030 |
Why?
| | Enzyme Induction | 1 | 2014 | 90 | 0.030 |
Why?
| | NAD | 1 | 2014 | 75 | 0.030 |
Why?
| | Cohort Studies | 2 | 2017 | 5426 | 0.030 |
Why?
| | Ventricular Remodeling | 1 | 2015 | 255 | 0.030 |
Why?
| | Blood Glucose | 2 | 2016 | 2100 | 0.030 |
Why?
| | HeLa Cells | 1 | 2014 | 612 | 0.020 |
Why?
| | Lipids | 1 | 2016 | 627 | 0.020 |
Why?
| | Transcriptome | 1 | 2018 | 876 | 0.020 |
Why?
| | Animals | 5 | 2014 | 35391 | 0.020 |
Why?
| | Genotype | 1 | 2017 | 1833 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3080 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2011 | 44 | 0.020 |
Why?
| | Thyroxine | 1 | 2011 | 62 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2011 | 100 | 0.020 |
Why?
| | Thyrotropin | 1 | 2011 | 109 | 0.020 |
Why?
| | Hypothyroidism | 1 | 2011 | 70 | 0.020 |
Why?
| | Health Behavior | 1 | 2016 | 743 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 297 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2014 | 584 | 0.020 |
Why?
| | Bone Development | 1 | 2009 | 50 | 0.020 |
Why?
| | Hypertrophy | 1 | 2009 | 122 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4404 | 0.020 |
Why?
| | Blood Pressure | 1 | 2016 | 1736 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 5756 | 0.020 |
Why?
| | Absorptiometry, Photon | 1 | 2009 | 248 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2010 | 372 | 0.020 |
Why?
| | Tibia | 1 | 2009 | 172 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1035 | 0.020 |
Why?
| | Adiponectin | 1 | 2009 | 235 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 949 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1501 | 0.020 |
Why?
| | Bone and Bones | 1 | 2009 | 294 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 723 | 0.020 |
Why?
| | Gene Expression | 1 | 2011 | 1465 | 0.020 |
Why?
| | Bone Density | 1 | 2009 | 463 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2010 | 2128 | 0.010 |
Why?
| | Cell Line | 1 | 2009 | 2784 | 0.010 |
Why?
| | Rats | 1 | 2010 | 5483 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 5455 | 0.010 |
Why?
| | Inflammation | 1 | 2010 | 2750 | 0.010 |
Why?
| | Insulin | 1 | 2009 | 2326 | 0.010 |
Why?
|
|
Rosenberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|